Literature DB >> 32336851

Antiviral agents against respiratory viruses.

Cecile L Tremblay1.   

Abstract

Entities:  

Year:  2001        PMID： 32336851      PMCID： PMC7172967          DOI： 10.1016/S0196-4399(01)89050-4

Source DB:  PubMed          Journal:  Clin Microbiol Newsl        ISSN： 0196-4399


× No keyword cloud information.
  102 in total

1.  Respiratory distress associated with zanamivir.

Authors:  J C Williamson; P S Pegram
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

Review 2.  Antiviral activity of amantadine: a review of laboratory and clinical data.

Authors:  J S Oxford; A Galbraith
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

3.  Oral ribavirin treatment of influenza A and B.

Authors:  D S Stein; C M Creticos; G G Jackson; J M Bernstein; F G Hayden; G M Schiff; D I Bernstein
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

4.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Authors:  R B Belshe; M H Smith; C B Hall; R Betts; A J Hay
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

5.  Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

Authors:  J A Hedrick; A Barzilai; U Behre; F W Henderson; J Hammond; L Reilly; O Keene
Journal:  Pediatr Infect Dis J       Date:  2000-05       Impact factor: 2.129

6.  Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Authors:  O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

7.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.

Authors:  L V Gubareva; M N Matrosovich; M K Brenner; R C Bethell; R G Webster
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

Review 8.  Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases.

Authors: 
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

9.  Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.

Authors:  M Baba; R Pauwels; J Balzarini; P Herdewijn; E De Clercq; J Desmyter
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

Authors:  C B Hall; J T McBride; E E Walsh; D M Bell; C L Gala; S Hildreth; L G Ten Eyck; W J Hall
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.